The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
Official Title: A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 in Combination With IDE397 in Subjects With Advanced MTAP-null Solid Tumors
Study ID: NCT05975073
Brief Summary: The main aims of this study are to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or the recommended combination dose of AMG 193 in combination with IDE397 in adult participants with metastatic or locally advanced MTAP-null solid tumors, and to evaluate the preliminary anti-tumor activity of AMG 193 in combination with IDE397 in adult participants with metastatic or locally advanced MTAP-null Non-Small-Cell Lung Cancer (NSCLC).
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
City of Hope National Medical Center, Duarte, California, United States
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
Community Health Network MD Anderson Cancer Center - North, Indianapolis, Indiana, United States
University of Michigan, Ann Arbor, Michigan, United States
Astera Cancer Care, East Brunswick, New Jersey, United States
Columbia University Medical Center, New York, New York, United States
Duke University Medical Center, Durham, North Carolina, United States
Prisma Health Upstate, Greenville, South Carolina, United States
Next Oncology, Irving, Texas, United States
The Queen Elizabeth Hospital, Woodville South, South Australia, Australia
Monash Medical Centre, Clayton, Victoria, Australia
Name: MD
Affiliation: Amgen
Role: STUDY_DIRECTOR